

Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Continuous Passive Motion (CPM) is addressed separately in medical policy 00020.

Services Are Not Covered

Based on review of available data, the Company considers the use of active and passive cooling devices or combination cooling and compression (cryopneumatic) devices (e.g., the Game Ready system) in the outpatient setting mainly for the comfort or convenience of the member is **not covered.****

Note: Cooling Devices Used in the Outpatient Setting are considered an exclusion in most member contracts.

Background/Overview

Cold and Compression Therapy

Use of ice packs and various bandages and wraps following surgery or musculoskeletal and soft tissue injury is common. A variety of manually operated and mechanical continuous cooling devices are commercially available.

The standard postoperative treatment for musculoskeletal surgeries consists of cryotherapy (cold therapy) and various types of compressive wraps. Both ice packs (with or without additives to maintain temperature) and cooling devices can provide cryotherapy. Circulating cooling devices are designed to provide a constant low temperature, which might provide additional benefit compared with the more variable temperature achieved with the intermittent replacement of ice packs. Noncirculating cooling devices might also allow less variable cooling due to the larger volume of ice stored in the insulated tank and the use of circulated ice water.

Noncirculating Cooling Devices

The CryoCuff^{®‡} and Polar Care Cub devices are examples of passive, noncirculating cooling devices. The CryoCuff device consists of an insulated container filled with iced water that is attached

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

to a compressive cuff. When the CryoCuff container is raised, the water fills and pressurizes the cuff. The amount of pressure is proportional to the height of the container. When body heat warms the water, the cooler is lowered and water drained. The cooler is then raised above the affected limb, and cold water refills the compressive cuff. The Polar Care Cub unit consists of pads held in place with elastic straps, which may also provide compression. The pads are attached to a built-in hand pump that circulates the water through the pads at the same time as increasing the compression around the joint.

Circulating Cooling Devices

In active, circulating cooling devices, a motorized pump circulates chilled water and may also provide pneumatic compression. For example, the AutoChill®‡ device, which may be used with a CryoCuff, consists of a pump that automatically exchanges water from the cuff to the cooler, eliminating the need for manual water recycling. The Hot/Ice Thermal Blanket is another circulating cooling device. It consists of 2 rubber pads connected by a rubber hose to the main cooling unit. Fluid is circulated via the hose through the thermal blankets. The temperature of the fluid is controlled by the main unit and can be either hot or cold. The Game Ready™‡ Accelerated Recovery System is a circulating cooling device combined with a pneumatic component. The system consists of various soft wraps and a computer-control unit to circulate the water through the wraps and to provide intermittent pneumatic compression. The Hilotherm®‡ Clinic circulates cooled water through preshaped thermoplastic polyurethane facial masks for use after different types of facial surgery. ThermaZone®‡ provides thermal therapy with pads specific to various joints as well as different areas of the head (front, sides, back, eyes). CTM 5000 and cTreatment are computer-controlled devices that provide cooling at a specific (11°C) and continuous temperature.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

A large number of circulating and noncirculating cooling devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process since 1976.

FDA product code: ILO.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

Table 1. Cooling Devices Cleared by the U.S. Food and Drug Administration

Device	Manufacturer	Date Cleared	510(k) No.	Indication
Device	Manufacturer	Date Cleared	510(k) No.	Indication
Armory Motion	Pain Management Technologies, Inc.	06/10/2022	K213097	To treat post-surgical and acute injuries to reduce swelling and pain
Ice Compression First, Duo, & Moove Systems	MksParis	1/11/2021	K193079	To treat post-surgical and acute injuries to reduce swelling and pain
Game Ready GRPro 2.1 System	Cool Systems, Inc (Dba Game Ready)	10/29/2019	K192114	To treat post-surgical and acute injuries to reduce swelling and pain
Polar Care Wave	Breg Inc	03/01/2019	K183702	To treat post-surgical and acute injuries to reduce swelling and pain
Therm-X, Therm-X At, Therm-X Pro Ath	Zenith Technical Innovations	5/10/2019 08/03/2018	K190854 K181149	To treat post-surgical and acute injuries to reduce swelling and pain

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

Description

Cooling devices use chilled water to decrease the local temperature of tissue. There are a variety of cooling devices available, ranging from gravity-fed devices that manually fill with iced water, to motorized units that both cool and circulate chilled water. These devices are typically used when ice packs would normally be applied (eg, after orthopedic surgical procedures).

Summary of Evidence

For individuals who have pain and/or swelling after knee surgery who receive a cooling device, the evidence includes several randomized controlled trials (RCTs) and a case-control study. Relevant outcomes are symptoms, functional outcomes, medication use, and resource utilization. Evidence on manually operated passive noncirculating cooling devices is limited by the control condition used in the trials. Studies on manually operated passive noncirculating cooling devices were limited by the control condition used in the trials. Studies that used either a no-icing control or infrequent ice applications did not provide sufficient evidence of comparative efficacy. Other studies provided no information on the frequency of ice changes, limiting interpretation of the results. Several randomized trials have compared active circulating cooling devices with standard intermittent icing or cold packs, and 2 of the larger trials found no significant benefit of the continuous cooling devices. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have pain and/or swelling after shoulder surgery who receive a cooling device, the evidence includes 2 RCTs. Relevant outcomes include symptoms, functional outcomes, medication use, and resource utilization. Evidence found that use of compressive cryotherapy produced no significant reduction in pain or medication use compared with the standard ice wrap. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have pain and/or swelling after facial surgery who receive a cooling device, the evidence includes several small RCTs and a pilot study. Relevant outcomes include symptoms, functional outcomes, medication use, and resource utilization. There have been mixed results regarding the intervention's efficacy in reducing neurologic problems as well as improving eye motility, diplopia, mandible functioning, and mouth opening compared with conventional cooling regimens. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2008 Input

In response to requests, input was received from 3 specialty societies and 3 academic medical centers while the policy was under review in 2008. Input was mixed regarding the medical necessity of continuous cooling devices.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Orthopaedic Surgeons

In 2016, the American Academy of Orthopaedic Surgeons released guidelines on the surgical management of osteoarthritis of the knee after knee arthroplasty. They state, "Moderate evidence supports that cryotherapy devices after knee arthroscopy (KA) do not improve outcomes."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT04185064 ^a	Randomized-Controlled Trial and Evaluation Cohort Study of Patients Using a Cryopneumatic Device After Open or Arthroscopic Shoulder Surgeries	250	Dec 2021 (recruiting)
NCT05095909	Utility of Intermittent Cryo-Compression Versus Traditional Icing Following Arthroscopic Rotator Cuff Repair	100	June 2024
Unpublished			
NCT02426515	Cryotherapy to Improve Outcomes in Lower Third Molar Surgery (COOL)	63	June 2018 (completed)

NCT: national clinical trial.

References

- 1. Schröder D, Pässler HH. Combination of cold and compression after knee surgery. A prospective randomized study. Knee Surg Sports Traumatol Arthrosc. 1994; 2(3): 158-65. PMID 7584198
- 2. Whitelaw GP, DeMuth KA, Demos HA, et al. The use of the Cryo/Cuff versus ice and elastic wrap in the postoperative care of knee arthroscopy patients. Am J Knee Surg. 1995; 8(1): 28-30; discussion 30-1. PMID 7866800
- 3. Healy WL, Seidman J, Pfeifer BA, et al. Cold compressive dressing after total knee arthroplasty. Clin Orthop Relat Res. Feb 1994; (299): 143-6. PMID 7907012

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

^a Denotes industry-sponsored or cosponsored trial.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

- 4. Thienpont E. Does advanced cryotherapy reduce pain and narcotic consumption after knee arthroplasty?. Clin Orthop Relat Res. Nov 2014; 472(11): 3417-23. PMID 25059851
- 5. Woolf SK, Barfield WR, Merrill KD, et al. Comparison of a continuous temperature-controlled cryotherapy device to a simple icing regimen following outpatient knee arthroscopy. J Knee Surg. Jan 2008; 21(1): 15-9. PMID 18300666
- 6. Ruffilli A, Buda R, Castagnini F, et al. Temperature-controlled continuous cold flow device versus traditional icing regimen following anterior cruciate ligament reconstruction: a prospective randomized comparative trial. Arch Orthop Trauma Surg. Oct 2015; 135(10): 1405-10. PMID 26141535
- 7. Ruffilli A, Castagnini F, Traina F, et al. Temperature-Controlled Continuous Cold Flow Device after Total Knee Arthroplasty: A Randomized Controlled Trial Study. J Knee Surg. Sep 2017; 30(7): 675-681. PMID 27903009
- 8. Coviello M, Abate A, Ippolito F, et al. Continuous Cold Flow Device Following Total Knee Arthroplasty: Myths and Reality. Medicina (Kaunas). Oct 27 2022; 58(11). PMID 36363493
- 9. Su EP, Perna M, Boettner F, et al. A prospective, multi-center, randomised trial to evaluate the efficacy of a cryopneumatic device on total knee arthroplasty recovery. J Bone Joint Surg Br. Nov 2012; 94(11 Suppl A): 153-6. PMID 23118406
- 10. Waterman B, Walker JJ, Swaims C, et al. The efficacy of combined cryotherapy and compression compared with cryotherapy alone following anterior cruciate ligament reconstruction. J Knee Surg. May 2012; 25(2): 155-60. PMID 22928433
- 11. Murgier J, Cailliez J, Wargny M, et al. Cryotherapy With Dynamic Intermittent Compression Improves Recovery From Revision Total Knee Arthroplasty. J Arthroplasty. Sep 2017; 32(9): 2788-2791. PMID 28465126
- 12. Kraeutler MJ, Reynolds KA, Long C, et al. Compressive cryotherapy versus ice-a prospective, randomized study on postoperative pain in patients undergoing arthroscopic rotator cuff repair or subacromial decompression. J Shoulder Elbow Surg. Jun 2015; 24(6): 854-9. PMID 25825138
- 13. Noyes MP, Denard PJ. Continuous Cryotherapy vs Ice Following Total Shoulder Arthroplasty: A Randomized Control Trial. Am J Orthop (Belle Mead NJ). Jun 2018; 47(6). PMID 29979799
- 14. Rana M, Gellrich NC, von See C, et al. 3D evaluation of postoperative swelling in treatment of bilateral mandibular fractures using 2 different cooling therapy methods: a randomized observer blind prospective study. J Craniomaxillofac Surg. Jan 2013; 41(1): e17-23. PMID 22626630
- 15. Rana M, Gellrich NC, Ghassemi A, et al. Three-dimensional evaluation of postoperative swelling after third molar surgery using 2 different cooling therapy methods: a randomized

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

observer-blind prospective study. J Oral Maxillofac Surg. Aug 2011; 69(8): 2092-8. PMID 21496998

- 16. Rana M, Gellrich NC, Joos U, et al. 3D evaluation of postoperative swelling using two different cooling methods following orthognathic surgery: a randomised observer blind prospective pilot study. Int J Oral Maxillofac Surg. Jul 2011; 40(7): 690-6. PMID 21411291
- 17. Modabber A, Rana M, Ghassemi A, et al. Three-dimensional evaluation of postoperative swelling in treatment of zygomatic bone fractures using two different cooling therapy methods: a randomized, observer-blind, prospective study. Trials. Jul 29 2013; 14: 238. PMID 23895539
- 18. McGrory BJ, Weber KL, Jevsevar DS, et al. Surgical Management of Osteoarthritis of the Knee: Evidence-based Guideline. J Am Acad Orthop Surg. Aug 2016; 24(8): e87-93. PMID 27355286

Policy History

I Unity IIIS	tory
Original Effective	ve Date: 06/28/2004
Current Effectiv	re Date: 02/12/2024
06/01/2004	Medical Director review
06/15/2004	Medical Policy Committee review
06/28/2004	Managed Care Advisory Council approval
12/07/2004	Medical Director review
12/14/2004	Medical Policy Committee review. Format revision. Name changed from Cryo
	Therapy to Cooling Devices Used in the Outpatient Setting. Policy/Guideline
	section revised to reflect member contract non-coverage of convenience items.
01/31/2005	Managed Care Advisory Council approval
07/07/2006	Format revision, including addition of FDA and or other governmental regulatory
	approval and rationale/source. Coverage eligibility unchanged.
01/10/2007	Medical Director review
01/17/2007	Medical Policy Committee approval
01/09/2008	Medical Director review
01/23/2008	Medical Policy Committee approval
01/07/2009	Medical Director review
01/14/2009	Medical Policy Committee approval. No change to coverage.
01/07/2010	Medical Director approval
01/20/2010	Medical Policy Implementation Committee approval. No change to coverage.
	Coding review.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

010/6/2011	Medical Director approval
01/19/2011	Medical Policy Implementation Committee approval. No change to coverage
02/02/2012	Medical Policy Committee review
02/15/2012	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged.
01/03/2013	Medical Policy Committee review
01/09/2013	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged.
01/09/2014	Medical Policy Committee review
01/15/2014	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged.
01/08/2015	Medical Policy Committee review
01/21/2015	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged.
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section
	removed.
01/07/2016	Medical Policy Committee review
01/22/2016	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
01/05/2017	Medical Policy Committee review
01/18/2017	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged
01/04/2018	Medical Policy Committee review
01/17/2018	Medical Policy Implementation Committee approval. Added combination cooling
	and compression (cryopneumatic) devices (e.g., the Game Ready system) to the
	services are not covered statement.
08/09/2018	Coding update
01/10/2019	Medical Policy Committee review
01/23/2019	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged.
01/03/2020	Medical Policy Committee review
01/08/2020	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

01/07/2021	Medical Policy Committee review				
01/13/2021	Medical Policy Implementation	Committee	approval.	Coverage	eligibility
	unchanged.				
06/21/2021	Coding update				
01/06/2022	Medical Policy Committee review				
01/12/2022	Medical Policy Implementation	Committee	approval.	Coverage	eligibility
	unchanged.				
01/05/2023	Medical Policy Committee review				
01/11/2023	Medical Policy Implementation	Committee	approval.	Coverage	eligibility
	unchanged.				
01/23/2023	Coding update				
01/04/2024	Medical Policy Committee review				
01/10/2024	Medical Policy Implementation	Committee	approval.	Coverage	eligibility
	unchanged.				

Next Scheduled Review Date: 01/2025

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	No codes
HCPCS	E0218, E0236
ICD-10 Diagnosis	All related diagnoses

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00139

Original Effective Date: 06/28/2004 Current Effective Date: 02/12/2024

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.